Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade

被引：0
|
作者：
Zhang, Xinmu [1 ]
Zhang, Li [2 ,3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll CAMS, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Liver Surg, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll CAMS, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Div Pulm & Crit Care Med, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll CAMS, Peking Union Med Coll Hosp, Div Pulm & Crit Care Med, State Key Lab Complex Severe & Rare Dis, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
来源：
JAMA ONCOLOGY | 2023年 / 9卷 / 04期
关键词：
D O I：
10.1001/jamaoncol.2022.7583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：569 / 570
页数：2
相关论文
共 50 条
  • [1] Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
    Ricciuti, Biagio
    Wang, Xinan
    Alessi, Joao, V
    Rizvi, Hira
    Mahadevan, Navin R.
    Li, Yvonne Y.
    Polio, Andrew
    Lindsay, James
    Umeton, Renato
    Sinha, Rileen
    Vokes, Natalie, I
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Lawrence, Marissa
    Vaz, Victor R.
    Leonardi, Giulia C.
    Plodkowski, Andrew J.
    Gupta, Hersh
    Cherniack, Andrew D.
    Tolstorukov, Michael Y.
    Sharma, Bijaya
    Felt, Kristen D.
    Gainor, Justin F.
    Ravi, Arvind
    Getz, Gad
    Schalper, Kurt A.
    Henick, Brian
    Forde, Patrick
    Anagnostou, Valsamo
    Janne, Pasi A.
    Van Allen, Eliezer M.
    Nishino, Mizuki
    Sholl, Lynette M.
    Christiani, David C.
    Lin, Xihong
    Rodig, Scott J.
    Hellmann, Matthew D.
    Awad, Mark M.
    [J]. JAMA ONCOLOGY, 2022, 8 (08) : 1160 - 1168
  • [2] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
    Di Huang
    Fan Zhang
    Haitao Tao
    Sujie Zhang
    Junxun Ma
    Jinliang Wang
    Zhefeng Liu
    Pengfei Cui
    Shixue Chen
    Ziwei Huang
    Zhaozhen Wu
    Lei Zhao
    Yi Hu
    [J]. Targeted Oncology, 2020, 15 : 93 - 100
  • [3] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
    Huang, Di
    Zhang, Fan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Wang, Jinliang
    Liu, Zhefeng
    Cui, Pengfei
    Chen, Shixue
    Huang, Ziwei
    Wu, Zhaozhen
    Zhao, Lei
    Hu, Yi
    [J]. TARGETED ONCOLOGY, 2020, 15 (01) : 93 - 100
  • [4] Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
    Schatz, Stefanie
    Falk, Markus
    Jori, Balazs
    Ramdani, Hayat O.
    Schmidt, Stefanie
    Willing, Eva-Maria
    Menon, Roopika
    Groen, Harry J. M.
    Diehl, Linda
    Kroeger, Matthias
    Wesseler, Claas
    Griesinger, Frank
    Hoffknecht, Petra
    Tiemann, Markus
    Heukamp, Lukas C.
    [J]. CANCERS, 2020, 12 (06) : 1 - 14
  • [5] The impact of genomic mutational status on PD-L1 expression and tumor mutation burden in non-small cell lung cancer
    Zhou, Qing
    Gu, Weiguang
    Fu, WenFan
    Mai, Shijie
    Lin, Daren
    Zhang, Shiyue
    Wang, Wenjing
    Zhang, Peng
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [6] Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
    Kim, H.
    Kwon, H. J. K.
    Kim, E. S. K.
    Han, Y. B.
    Lee, J.
    Kim, S. H.
    Kim, Y. J.
    Lee, J.
    Chung, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S470
  • [7] PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Dong, Aoran
    Zhao, Yiming
    Li, Zhihua
    Hu, Hai
    [J]. JOURNAL OF GENE MEDICINE, 2021, 23 (02):
  • [8] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [9] Plasma cell free PD-L1 RNA expression correlated with tissue PD-L1 immunohistochemical staining and tumor mutation burden in non-small cell lung cancer.
    Walker, Paul R.
    Bowling, Mark
    Sharma, Nitika
    Namireddy, Praveen
    Parent, Teresa
    Cherry, Cynthia R.
    Yeh, Chen-Hsiung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels (vol 8, pg 1160, 2022)
    Ricciuti, B.
    Wang, X.
    Alessi, J., V
    [J]. JAMA ONCOLOGY, 2022, 8 (11) : 1702 - 1702
12345